1Kim JY, Lim S J, Park K. Cyclooxygenase - 2 and HER - 2 expres- sion in colorectal carcinoma assessed using tissue microarrays [ J ]. Appl i mmunohistochem Mol Morphol, 2004,12 ( 1 ) :67 - 70.
3Stern D F, Heffernan P A, Wenberg R A, et al. a product of the neu proto - oncogene, is a recep torlike protein associated with tyrosine kinase activity [ J]. Mol Cell Biol, 1986,6 : 1729 - 1740.
4Essapen S,Thomas H, Green M, et al. The expression and prognostic significance of HER -2 in colorectal cancer and its relationship with clinicopathological parameters [ J ]. Int J Oncol,2004,24 ( 2 ) : 241 - 248.
5Half E, Broaddus R, Danenberg KD, et al. HER - 2 receptor expression, localization,and activation in colorectal cancer cell lines and human tumors [ J ]. Int J Cancer,2004,108 (4) :540 - 548.
7Osako T, Miyahara M, Uchino S, et al. Immunohistochemical study of HER- 2 protein in colorectal cancer and the correlations with paient survival [J]. Oncology, 1998, 55(4) :548 -555.
8Mckay JA, Loane JF, Ross VG, et al. C - erbB - 2 is not a major factor in the development of colorectal cancer[ J]. Br J Cancer,2002, 86(4) :568 -573.
9Michael Pohl I, Stricker A, Schoeneck,et al. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo [ J ]. Cancer Res Clin Oncol, 2009, 135:1377 - 1386.
10Mukai K,Yasutomi Y,Watanabe M, et aL HER - 2 peptide - specific CD8( + ) T cells are proportionally detectable long after mul- tiple DNA vaccinations [ J ]. Genether,2002,9 ( 13 ) :879 - 885.
